Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current HIV Research
  4. Volume 22, Issue 5
  5. Article
Volume 22, Issue 5
  • ISSN: 1570-162X
  • E-ISSN: 1873-4251

Abstract

Background

Virological failure (VF) among children remains concerning, with high risks of HIV drug resistance (HIVDR) emergence and increased disease progression. Therefore, monitoring of viral non-suppression and emerging HIVDR is crucial, especially in the frame of sociopolitical unrest.

Objective

The study sought to determine the prevalence of VF and evaluate the acquired HIVDR and viral genetic diversity among children in the Northwest region of Cameroon during the ongoing sociopolitical crisis.

Methods

A cross-sectional facility-based study was conducted among HIV-infected children aged ≤18 years, receiving antiretroviral therapy (ART) in urban and rural settings of Northwest Cameroon, from November 2017 through May 2018. Viral load (VL) was done using the Abbott m2000RealTime. Unsuppressed VL was defined as viral load ≥1,000 copies/ml. HIVDR testing was performed by sequencing of HIV-1 protease-reverse transcriptase at the Chantal Biya International Reference Center (CIRCB) using an in-house protocol. Drug resistance mutations (DRM) were interpreted using Stanford HIVdbv8.5 and phylogeny using MEGAv.6. Data were compared between urban and rural areas with <0.05 considered statistically significant.

Results

A total of 363 children were recruited, average age of 12 years (urban) and 8 years (rural). VL coverage was 100% in the urban setting and 77% in the rural setting. Overall, VF was 40.5% (39% [130/332] in the urban setting and 41% (13/31) in the rural setting; =0.45). Overall, viral undetectability (defined as VL<40 copies/ml) was 45.5% (46% (urban) and 45% (rural); =0.47). Among those experiencing confirmed virological failure and who were successfully sequenced (n=35), the overall rate of HIVDR was 100% (35/35). By drug class, HIVDR rates were 97.1% (34/35) for non-nucleoside reverse transcriptase inhibitors (NNRTIs), 97.1% (34/35) for NRTIs and 17.1% (6/35) for protease inhibitors (22.7% (5/22) in the urban setting and 7.7% [1/13] in the rural setting). CRF02_AG was the most prevalent viral clade (75%), followed by other recombinants (09_cpx, 11_cpx, 13_cpx, 22_01A1, 37_cpx) and pure subtypes (A1, F2, G, H).

Conclusion

In this population of children and adolescents living with HIV in a context of socio-political instability in the North-West region of Cameroon, rates of viral non-suppression are high, and accompanied by HIVDR selection. Our findings suggest the need for a more differentiated care of these CAHIV, especially those in these regions faced with significant socio-economic and health impacts due to the ongoing crisis.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X319028240830064946
2024-10-07
2025-01-10

  • From This Site

    /content/journals/chr/10.2174/011570162X319028240830064946
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HIV data and statistics.2024Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics(accessed on 27-8-2024)
  2. Global and regional trends.2024Available from:https://data.unicef.org/topic/hivaids/global-regional-trends/(accessed on 27-8-2024)
  3. BiyazinY. WondwossenK. WubieA.B. GetachewM. GebremichaelB. Survival and predictors of mortality among HIV positive children on antiretroviral therapy in public hospitals.J. Pharm. Policy Pract.20221514810.1186/s40545‑022‑00448‑635978382
     [Google Scholar]
  4. UNAIDS data.2021Available from:https://www.unaids.org/en/resources/documents/2021/2021_unaids_data(accessed on 27-8-2024)
  5. MutaleW. HerceM.E. Closing the gap in paediatric HIV infections: how available tools and technology can accelerate progress towards ending AIDS by 2030.Lancet2024403104341313131510.1016/S0140‑6736(24)00366‑038484754
     [Google Scholar]
  6. Barlow-MoshaL. MusiimeV. DaviesM.A. PrendergastA.J. MusokeP. SiberryG. PenazzatoM. Universal antiretroviral therapy for HIV-infected children: A review of the benefits and risks to consider during implementation.J. Int. AIDS Soc.20172012155210.7448/IAS.20.1.2155228691434
     [Google Scholar]
  7. TeasdaleC.A. AbramsE.J. YuenglingK.A. LambM.R. WangC. VitaleM. HawkenM. MelakuZ. Nuwagaba-BiribonwohaH. El-SadrW.M. Expansion and scale-up of HIV care and treatment services in four countries over ten years.PLoS One2020154e023166710.1371/journal.pone.023166732298331
     [Google Scholar]
  8. TebitD.M. ArtsE.J. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease.Lancet Infect. Dis.2011111455610.1016/S1473‑3099(10)70186‑921126914
     [Google Scholar]
  9. World Bank Open Data.2024https://data.worldbank.org
  10. WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring.2021Available from:https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring(accessed on 27-8-2024)
  11. MuluA. MaierM. LiebertU.G. Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.PLoS One20171210e018661910.1371/journal.pone.018661929049402
     [Google Scholar]
  12. HIV drug resistance – brief report 2024.2024Available from:https://www.who.int/publications/i/item/9789240086319(accessed on 27-8-2024)
  13. van SchalkwykC. MahyM. JohnsonL.F. Imai-EatonJ.W. Updated data and methods for the 2023 UNAIDS HIV estimates.J. Acquir. Immune Defic. Syndr.2024951SSuppl.e1e410.1097/QAI.000000000000334438180734
     [Google Scholar]
  14. DANGER: UNAIDS Global AIDS Update 2022. Geneva: Joint United Nations Programme on HIV/AIDS; 2022. Licence: CC BY-NC-SA 3.0 IGO.2022Available from:https://www.unaids.org/sites/default/files/media_asset/2022-global-aids-update_en.pdf(accessed on 27-8-2024)
  15. West and Central Africa left behind in Global HIV response.2017Available from:https://www.unicef.org/wca/press-releases/west-and-central-africa-left-behind-global-hiv-response(accessed on 27-8-2024)
  16. BekoloC.E. KouanfackC. AteudjieuJ. BechemE.T. NdesoS.A. TendengforN. NsaghaD.S. ChoukemS.P. The declining trend in HIV prevalence from population-based surveys in Cameroon between 2004 and 2018: myth or reality in the universal test and treat era?BMC Public Health202323147910.1186/s12889‑023‑15374‑836915039
     [Google Scholar]
  17. Comite National de Lutte le SIDA (CNLS). Rapport Annuel des activitees de lutte contre le VIH et SIDA.2021Available from: https://cnls.cm/index.php/rapports-dactivites/(accessed on 27-8-2024)
  18. AwungafacG. AminE.T. FualefacA. TakahN.F. AgyingiL.A. NwobegahayJ. OndoaP. NjukengP.A. Viral load testing and the use of test results for clinical decision making for HIV treatment in Cameroon: An insight into the clinic-laboratory interface.PLoS One2018136e019868610.1371/journal.pone.019868629889862
     [Google Scholar]
  19. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV.2024Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new(accessed on 27-8-2024)
  20. BekoloC.E. NdesoS.A. GougueC.P. MoifoL.L. MangalaN. TchendjouP. MbohE. AteudjieuJ. TendongforN. NsaghaD.S. Halle-EkaneG.E. ChoukemS.P. The effect of the Universal Test and Treat policy uptake on CD4 count testing and incidence of opportunistic infections among people living with HIV infection in Cameroon: a retrospective analysis of routine data.Dialogues Health2023210012010.1016/j.dialog.2023.10012038515498
     [Google Scholar]
  21. Antiretoviral therapy.2021Available from:https://www.ncbi.nlm.nih.gov/books/NBK572730/(accessed on 27-8-2024)
  22. MuriL. GamellA. NtamatungiroA.J. GlassT.R. LuwandaL.B. BattegayM. FurrerH. HatzC. TannerM. FelgerI. KlimkaitT. LetangE. KIULARCO Study Group Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania.AIDS2017311617010.1097/QAD.000000000000127327677163
     [Google Scholar]
  23. DambayaB. FokamJ. NgoufackE.S. TakouD. SantoroM.M. TétoG. BeloumouG.A. MouafoL.C.M. KamgaingN. SossoS.M. BillongS.C. Njom NlendA.E. SobzeM.S. NkenfouC. KokiP.N. NjiokouF. ColizziV. PernoC.F. NdjoloA. HIV-1 drug resistance and genetic diversity among vertically infected cameroonian children and adolescents.Explor. Res. Hypothesis Med.202052536110.14218/ERHM.2019.00031
     [Google Scholar]
  24. FokamJ. TakouD. TetoG. NforbihS.E. KomeO.P. SantoroM.M. NgoufackE.S. EyongetahM. PalmerD. FokunangE.T. FokunangC.N. ColizziV. PernoC.F. NdjoloA. Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon.PLoS One2020157e023595810.1371/journal.pone.023595832692778
     [Google Scholar]
  25. FokamJ. TakouD. NjumeD. PaboW. SantoroM.M. Njom NlendA-E. BeloumouG. SossoS. MoudourouS. TetoG. DambayaB. DjupsaS. Tetang NdiangS. AtebaF.N. BillongS.C. KamtaC. BalaL. LamboV. TalaV. Chenwi AmbeC. MpouelM.L. CappelliG. ChamF. NdipR. MbuagbawL. Koki NdomboP. Ceccherini-SilbersteinF. ColizziV. PernoC-F. NdjoloA. Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon.HIV Med.202122756758010.1111/hiv.1309533792134
     [Google Scholar]
  26. HuntG.M. LedwabaJ. SalimoA. KalimasheM. DinhT.H. JacksonD. ShermanG. PurenA. NganduN.K. LombardC. MorrisL. GogaA. Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4–8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011–12 and 2012–13.BMC Infect. Dis.201919S1Suppl. 178710.1186/s12879‑019‑4339‑y31526373
     [Google Scholar]
  27. FokamJ. ElatJ.B.N. BillongS.C. KembouE. NkwescheuA.S. ObamN.M. EssianeA. TorimiroJ.N. EkanmianG.K. NdjoloA. ShiroK.S. BissekA.C.Z.K. Monitoring HIV drug resistance early warning indicators in cameroon: A study following the revised world health organization recommendations.PLoS One2015106e012921010.1371/journal.pone.012921026083364
     [Google Scholar]
  28. FokamJ. NangmoA. WandumC. TakouD. SantoroM.M. NlendA.E.N. AtebaF.N. NdomboP.K. KamgaingN. KamtaC. EssianeA. LamboV. FokunangC. MbanyaD. ColizziV. PernoC.F. NdjoloA. Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon.AIDS Res. Ther.20201711410.1186/s12981‑020‑00270‑732398107
     [Google Scholar]
  29. Operational guidelines for the implementation of the “test and treat” strategy in cameroon.Available from:https://www.differentiatedservicedelivery.org/wp-content/uploads/Cameroon.pdf(accessed on 27-8-2024)
  30. JordanM.R. PenazzatoM. CournilA. VubilA. JaniI. HuntG. CarmonaS. MaphalalaG. MthethwaN. WateraC. KaleebuP. MusanhuC.C. Mtapuri-ZinyoweraS. DzangareJ. PeetersM. YangC. ParkinN. BertagnolioS. Human immunodeficiency virus (HIV) drug resistance in african infants and young children newly diagnosed with HIV: A multicountry analysis.Clin. Infect. Dis.201765122018202510.1093/cid/cix69829020335
     [Google Scholar]
  31. FokamJ. ChenwiC.A. TalaV. TakouD. SantoroM.M. TetoG. DambayaB. AnubodemF. SemengueE.N.J. BeloumouG. DjupsaS. AssomoE. FokunangC. AlteriC. BillongS. BoubaN.P. AjehR. ColizziV. MbanyaD. Ceccherini-SilbersteinF. PernoC.F. NdjoloA. Pre-treatment HIV drug resistance and genetic diversity in cameroon: Implications for first-line regimens.Viruses2023157145810.3390/v1507145837515146
     [Google Scholar]
  32. Global action plan on HIV drug resistance 2017–2021.2017Available from:https://www.who.int/publications-detail-redirect/978-92-4-151284-8(accessed on 27-8-2024)
  33. ParkinN. HarriganP.R. InzauleS. BertagnolioS. Need assessment for HIV drug resistance testing and landscape of current and future technologies in low- and middle-income countries.PLOS Glob. Public Health2023310e000194810.1371/journal.pgph.000194837851634
     [Google Scholar]
  34. AgwandaB. NyaderaI.N. AsalU.Y. Cameroon and the Anglophone Crisis.The Palgrave Encyclopedia of Peace and Conflict Studies.InternetChamSpringer International Publishing202011110.1007/978‑3‑030‑11795‑5_115‑1
     [Google Scholar]
  35. EkahR.E. The anglophone crisis in cameroon: A geopolitical analysis.Euro. Sci. J.20201532141
     [Google Scholar]
  36. Global responses to cameroon’s anglophone crisis: The inadequate international efforts to end the world’s most neglected conflict.2022Available from:https://saisreview.sais.jhu.edu/cameroon-anglophone-crisis-global-response/(accessed on 27-8-2024)
  37. EposiT.K. EwangeM.P. Education under attack in cameroon: The effects of the socio-political crisis on the anglophone sub-system of education of the anglophone regions of cameroon.Int. J. Integrat. Edu.2021412156171
     [Google Scholar]
  38. TaweT.I. BomonoH.Y. The Anglophone crisis and migratory patterns in Cameroon: Some social and economic implications for women.Sociology, Social Policy and EducationElgar Online2022
     [Google Scholar]
  39. NarondoM.D.I. The impact of the anglophone crisis on education and health in the north west and south west regions.Cameroon2023
     [Google Scholar]
  40. HaddisonE.C. JuliusC.E. KaginaB.M. Health services utilisation before and during an armed conflict; Experiences from the Southwest region of Cameroon.2020published on 26 Oct, 2020.
     [Google Scholar]
  41. FonkwoJ. BesongM. NgongJ. GlazierA. TalawaD. AlioA. The effect of the anglophone crisis on youth sexual and reproductive health in the Northwest region of Cameroon: A qualitative study.J. Glob. Health Rep.20237e202304010.29392/001c.84239
     [Google Scholar]
  42. McCluskeyS.M. SiednerM.J. MarconiV.C. Management of virologic failure and HIV drug resistance.Infect. Dis. Clin. North Am.201933370774210.1016/j.idc.2019.05.00431255384
     [Google Scholar]
  43. FokamJ. SalpiniR. SantoroM.M. CentoV. D’ArrigoR. GoriC. PernoC.F. ColizziV. NanfackA. GwomL.C. CappelliG. TakouD. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon.Arch. Virol.201115671235124310.1007/s00705‑011‑0982‑321465085
     [Google Scholar]
  44. MakadzangeA.T. Higgins-BiddleM. ChimukangaraB. BirriR. GordonM. MahlanzaT. McHughG. van DijkJ.H. Bwakura-DangarembiziM. Ndung’uT. MasimirembwaC. PhelpsB. AmzelA. OjikutuB.O. WalkerB.D. NdhlovuC.E. Clinical, virologic, immunologic outcomes and emerging HIV drug resistance patterns in children and adolescents in public art care in Zimbabwe.PLoS One20151012e014405710.1371/journal.pone.014405726658814
     [Google Scholar]
  45. MekolleJ.E. TshimwangaK.E. OngehN.J. AgbornkwaiA.N. AmadeusO.A. EsaI. MekolleK.E. ForbinakeN.A. NkfusaiC.N. AtangaP.N. Political instability and hiv/aids response in the south west and north west regions of Cameroon: A qualitative study.BMC Public Health2023231215510.1186/s12889‑023‑16994‑w37924012
     [Google Scholar]
  46. FokamJ. SalpiniR. SantoroM.M. CentoV. PernoC.F. ColizziV. NdumbeP.M. Fokunang NtungenC. Ndiang TetangS.M. NanfackA.J. Takou KomegoD.A. CappelliG. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon.Pediatr. Infect. Dis. J.201130121062106810.1097/INF.0b013e31822db54c21817951
     [Google Scholar]
  47. DjiyouA.B.D. PendaC.I. MadecY. NgondiG.D. MoukokoA. EboumbouC.E. AghokengA.F. Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia.J. Antimicrob. Chemother.202378122938294210.1093/jac/dkad33437921335
     [Google Scholar]
  48. CarrA. MackieN.E. ParedesR. RuxrungthamK. HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective.Antivir. Ther.20232851359653523120116210.1177/1359653523120116237749751
     [Google Scholar]
  49. SeyedAlinaghiS. AfsahiA.M. MoradiA. ParmoonZ. HabibiP. MirzapourP. DashtiM. GhasemzadehA. KarimiE. SanaatiF. HamediZ. MollaA. MehraeenE. DadrasO. Current ART, determinants for virologic failure and implications for HIV drug resistance: An umbrella review.AIDS Res. Ther.20232017410.1186/s12981‑023‑00572‑637884997
     [Google Scholar]
  50. PetingerC. CrowleyT. van WykB. Experiences of adolescents living with HIV on transitioning from pediatric to adult HIV care in low and middle-income countries: A qualitative evidence synthesis protocol.PLoS One2024192e029618410.1371/journal.pone.029618438315638
     [Google Scholar]
  51. HIV and AIDS.2021Available from: https://www.who.int/fr/news-room/fact-sheets/detail/hiv-aids?gad_source=1&gclid=CjwKCAjw8rW2BhAgEiwAoRO5rLJGT2u4NHFXTGIOiGlXoTPSqbqOE5It13Y3JRov3QIvwZLgIpWMlhoCwCEQAvD_BwE(accessed on 27-8-2024)
  52. KemnicT.R. GulickP.G. HIV Antiretroviral Therapy.StatPearls.InternetTreasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  53. PhamM.D. NguyenH.V. AndersonD. CroweS. LuchtersS. Viral load monitoring for people living with HIV in the era of test and treat: Progress made and challenges ahead – a systematic review.BMC Public Health2022221120310.1186/s12889‑022‑13504‑235710413
     [Google Scholar]
  54. PellowskiJ.A. Barriers to care for rural people living with HIV: A review of domestic research and health care models.J. Assoc. Nurses AIDS Care201324542243710.1016/j.jana.2012.08.00723352771
     [Google Scholar]
  55. TemereancaA. RutaS. Strategies to overcome HIV drug resistance-current and future perspectives.Front. Microbiol.202314113340710.3389/fmicb.2023.113340736876064
     [Google Scholar]
  56. BertrandA. The Socio-economic Consequences of the Anglophone Crisis in Cameroon (November 2016-August 2019), A Cause for an Indispensable Concern.GSJ201681114411461
     [Google Scholar]
  57. OmamL.A. JarmanE. EkokobeW. EvonA. OmamE.N. Mobile clinics in conflict-affected communities of North West and South West regions of Cameroon: An alternative option for differentiated delivery service for internally displaced persons during COVID-19.Confl. Health20211519010.1186/s13031‑021‑00427‑934906187
     [Google Scholar]
  58. RancanI. CassolC. GrazianiL. TilliM. MalcontentiC. RussoC. BottanelliM. BracchittaF. PapaioannuR. LabateL. MoraS. BezenchekA. ShallvariA. Di BiagioA. RossettiB. Trend over time of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA).HIV Med.202324111150115710.1111/hiv.1352537439411
     [Google Scholar]
  59. RiouJ. DupontC. BertagnolioS. GuptaR.K. KouyosR.D. EggerM. L AlthausC. Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: A modelling study.BMC Infect. Dis.2021211104210.1186/s12879‑021‑06757‑634620119
     [Google Scholar]
  60. WertheimJ.O. OsterA.M. JohnsonJ.A. SwitzerW.M. SaduvalaN. HernandezA.L. HallH.I. HeneineW. Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network.Virus Evol.201731vex00810.1093/ve/vex00828458918
     [Google Scholar]
  61. RakhmaninaN. Are we ready for long-acting HIV treatment for adolescents?Lancet HIV2024114e200e20110.1016/S2352‑3018(24)00039‑038538156
     [Google Scholar]
  62. CissyM.K. Randomized trial of cabotegravir and rilpivirine long-acting in Africa (CARES): Week 48 results.CROIMarch 3-6, 2024, Denver, Colorado, pp.1.
     [Google Scholar]
  63. JeffreyJ.L. St ClairM. WangP. WangC. LiZ. BeloorJ. TalaricoC. FridellR. KrystalM. WhiteC.T. GriffithS. D’AmicoR. SmithK. Van EygenV. VingerhoetsJ. VandermeulenK. SpreenW. van LunzenJ. Impact of integrase sequences from HIV-1 subtypes A6/A1 on the in vitro potency of cabotegravir or rilpivirine.Antimicrob. Agents Chemother.2022663e017022110.1128/aac.01702‑2134978890
     [Google Scholar]
  64. CervoA. RussoA. Di CarloD. De VitoA. FabeniL. D’AnnaS. DucaL. ColpaniA. FoisM. ZauliB. MancarellaG. CarraroA. BezenchekA. Cozzi-LepriA. SantoroM.M. ARCA Study Group Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort.J. Glob. Antimicrob. Resist.20233414114410.1016/j.jgar.2023.07.00637453495
     [Google Scholar]
  65. von WylV. KlimkaitT. YerlyS. NiccaD. FurrerH. CavassiniM. CalmyA. BernasconiE. BöniJ. AubertV. GünthardH.F. BucherH.C. GlassT.R. Swiss HIV Cohort Study Adherence as a predictor of the development of class-specific resistance mutations: The Swiss HIV Cohort Study.PLoS One2013810e7769110.1371/journal.pone.007769124147057
     [Google Scholar]
  66. ShaferR.W. SchapiroJ.M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.AIDS Rev.2008102678418615118
     [Google Scholar]
  67. WensingA.M. CalvezV. Ceccherini-SilbersteinF. CharpentierC. GünthardH.F. ParedesR. ShaferR.W. RichmanD.D. 2022 update of the drug resistance mutations in HIV-1.Top. Antivir. Med.202230455957436375130
     [Google Scholar]
  68. EdwardsZ. IngoldC.J. AzmatC.E. Zidovudine.StatPearls.InternetTreasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  69. O’RourkeJ. TownsendC.L. MilanziE. CollinsI.J. CastroH. JuddA. VicariM. JessonJ. LeroyV. PenazzatoM. RenaudF. Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: A systematic review.J. Int. AIDS Soc.2023262e2603710.1002/jia2.2603736823283
     [Google Scholar]
  70. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.Available from: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/tenofovir-df(accessed on 27-8-2024)
  71. National guidelines on HIV care.Available from:https://hivpreventioncoalition.unaids.org/en/resources/national-guidelines-hiv-care(accessed on 27-8-2024)
  72. MazzutiL. MelenguT. FalascaF. CalabrettoM. CellaE. CiccozziM. MezzaromaI. IaianiG. SpazianteM. d’EttorreG. FimianiC. VulloV. AntonelliG. TurrizianiO. Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience.J. Glob. Antimicrob. Resist.20202029830310.1016/j.jgar.2019.08.02431518723
     [Google Scholar]
  73. AbdullahiA. DiazA.G. FopoussiO.M. BeloukasA. DefoV.F. KouanfackC. TorimiroJ. GerettiA.M. A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.J. Antimicrob. Chemother.202479233934810.1093/jac/dkad38638153241
     [Google Scholar]
  74. FokamJ. ChenwiC.A. TakouD. SantoroM.M. TalaV. TetoG. BeloumouG. SemengueE.N.J. DambayaB. DjupsaS. KembouE. BoubaN.P. AjehR. CappelliG. MbanyaD. ColizziV. Ceccherini-SilbersteinF. PernoC.F. NdjoloA. Laboratory based surveillance of HIV-1 acquired drug resistance in cameroon: Implications for use of tenofovir-lamivudine-dolutegravir (TLD) as second- or third-line regimens.Viruses2023158168310.3390/v1508168337632026
     [Google Scholar]
  75. Ngoufack Jagni SemengueE. FokamJ. EtameN.K. MolimbouE. ChenwiC. TakouD. Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based firstline art in cameroon: An evidence of a successful transition model.Viruses Journal.2022Submitted
     [Google Scholar]
  76. Ngoufack Jagni SemengueE. SantoroM.M. NdzeV.N. Ka’eA.C. YagaiB. NkaA.D. DambayaB. TakouD. TetoG. FabeniL. ColizziV. PernoC.F. Ceccherini-SilbersteinF. FokamJ. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis.PLOS Glob. Public Health2022210e000082610.1371/journal.pgph.000082636962573
     [Google Scholar]
  77. FokamJ. Ngoufack Jagni SemengueE. ArmeniaD. TakouD. DambayaB. TetoG. ChenwiC.A. NkaA.D. BeloumouG.A. NdjeyepS.C.D. TchouaketM.C.T. FainguemN. SossoS.M. ColizziV. PernoC.F. NdjoloA. Ceccherini-SilbersteinF. SantoroM.M. High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: Toward a successful transition to dolutegravir-based regimens in low and middle-income countries.Diagn. Microbiol. Infect. Dis.2022102211557410.1016/j.diagmicrobio.2021.11557434864527
     [Google Scholar]
  78. JabłonowskaE. SiwakE. Bociąga-JasikM. GąsiorowskiJ. KalinowskaA. Firląg BurkackaE. Wójcik-CichyK. PiątekA. CielniakI. HorbanA. Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.PLoS One2019141e021047610.1371/journal.pone.021047630653541
     [Google Scholar]
/content/journals/chr/10.2174/011570162X319028240830064946
Loading
Rates of Viral Non-Suppression and Acquired HIV-1 Drug Resistance Emergence among Children during the Sociopolitical Crisis in the Northwest Region of Cameroon: A Call for Improved Monitoring Strategies
Current HIV Research 22, 336 (2024); https://doi.org/10.2174/011570162X319028240830064946
/content/journals/chr/10.2174/011570162X319028240830064946
/content/journals/chr/10.2174/011570162X319028240830064946
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antiretroviral therapy; drug resistance; HIV drug resistance; Paediatric; viral load; virological failure
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test